Skip to main content
. 2008 May 27;98(11):1736–1740. doi: 10.1038/sj.bjc.6604382

Table 2. Clinical trials of bisphosphonates to prevent metastasis.

Agent and trial descriptor Setting Treatment and duration Study size and status
Clodronate (oral)
 NSABP-B34 Stage I–III breast cancer 3 years clodronate vs placebo 3400 Accrual complete
         
Zoledronic acid (iv)
 AZURE Stage II/III breast cancer 5 years zoledronic acid vs control 3360 Accrual complete
 Z-FAST/ZO-FAST/EZO-FAST Stage I–III breast cancer Immediate vs delayed zoledronic acid 2193 Accrual complete
 ABCSG XII Stage I-II breast cancer 6 monthly zoledronic acid vs control 1800 Accrual complete
 SUCCESS Stage I–III breast cancer 3 vs 5 years zoledronic acid 3754 Acccrual ongoing
 ZEUS High-risk prostate cancer 3 years zoledronic acid vs control 1433 Accrual complete
 2419 Stage IIIA/IIIB NSCLC 2 years zoledronic acid vs control 446 Accrual ongoing
         
Ibandronate (oral)
 GAIN Stage II/III breast cancer 2 years ibandronate vs control >3000 Accrual ongoing
         
Others
 S0307/Intergroup Stage I–III breast cancer 3 years clodronate vs zoledronic acid vs ibandronate 4500 Accrual ongoing